Related Experiment Video

Updated: Aug 20, 2026

Facial Nerve Surgery in the Rat Model to Study Axonal Inhibition and Regeneration
05:04

Facial Nerve Surgery in the Rat Model to Study Axonal Inhibition and Regeneration

Published on: May 5, 2020

Treatment of aberrant facial nerve regeneration with botulinum toxin A

C N Chua1, F Quhill, E Jones

  • 1Oxford Eye Hospital Radcliffe Infirmary, Oxford, UK. chuaoxford@hotmail.com

Orbit (Amsterdam, Netherlands)
|December 14, 2004
PubMed
Abstract

Insights

Low-dose botulinum toxin type A (BTX-A) effectively treats eyelid synkinesia from aberrant facial nerve regeneration with fewer side effects like ptosis. Lower doses proved as effective as higher doses in this study.

Area of Science:

  • Neurology
  • Ophthalmology
  • Regenerative Medicine

Background:

  • Aberrant facial nerve regeneration can cause eyelid synkinesia, impacting patient quality of life.
  • Botulinum toxin type A (BTX-A) is a potential treatment for such conditions.

Observation:

  • A prospective study treated five patients with eyelid synkinesia using varying doses of BTX-A (Dysport).
  • Treatments involved injections into the orbicularis oculi muscle.

Findings:

  • BTX-A effectively reduced synkinesia in all patients, with lower doses showing comparable efficacy to higher doses.
  • The mean duration of synkinesia abolition was three months.
  • Ptosis occurred in two patients treated with higher doses but not with the lowest dose (40 units).

Implications:

  • Low-dose BTX-A is an effective treatment for aberrant facial nerve regeneration-induced synkinesia.
  • Reduced dosage of BTX-A may minimize the risk of adverse effects such as ptosis.
  • Further research into optimal BTX-A dosing for facial nerve disorders is warranted.

More Related Videos

Single-stage Dynamic Reanimation of the Smile in Irreversible Facial Paralysis by Free Functional Muscle Transfer19:53

Single-stage Dynamic Reanimation of the Smile in Irreversible Facial Paralysis by Free Functional Muscle Transfer

Published on: March 1, 2015

Related Concept Videos

Botulism01:22

Botulism

Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...